Latest:
Robotic Navigational Bronchoscopy Advances Diagnosis of Early-Stage Lung Cancer
Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Glenn J. Hanna, MD
Glenn J. Hanna, MD, is the director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program) and director of the Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School
Latest:
Dr Hanna on the Pharmacokinetic Profile of Micvotabart Pelidotin in HNSCC
Glenn J. Hanna, MD, discusses the preliminary antitumor activity and manageable safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.
Megan Melody, MD
Megan Melody, MD, is a hematologist/oncologist at Tampa General Hospital (TGH) and TGH Cancer Center.
Latest:
Dr Melody on the Influence of Female Mentorship on Her Research Career in Hematologic Oncology
Megan Melody, MD, discusses the importance of female mentorship on her career development as a hematologist/oncologist.
Timothy Schmidt, MD, University of Wisconsin
Latest:
Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple Myeloma
Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.
Sohail Dhanji, MD
Latest:
Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer
Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.
Ritesh R. Kotecha, MD
Ritesh R. Kotecha, MD is a medical oncologist specializing in the care of people with genitourinary cancers, including kidney cancer, bladder cancer, prostate cancer, and testicular cancer.
Latest:
Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC
Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.
Jordyn Silverstein, MD
Jordyn Silverstein, MD, is a hematology/oncology fellow at UCLA Health.
Latest:
Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer
Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.
Kai Conrad Cecil Johnson, MD
Latest:
Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast Cancer
Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.
Lynn G. Feun, MD
Latest:
Dr Feun on the Evolving Treatment Paradigm in HCC
Lynn G. Feun, MD, discusses the evolution of treatment approaches in hepatoceullar carcinoma, the influence of immunotherapies on patient outcomes in this armamentarium, and ongoing avenues of investigation within in the field of HCC management.